First multidisciplinary recommendations on management of arrhythmias in ACS patients

August 30, 2014

Barcelona, Spain - Saturday 30 August 2014: The first multidisciplinary recommendations on the management of arrhythmias in patients with acute coronary syndromes (ACS) are published today in EP Europace.

The position paper was written jointly by the European Heart Rhythm Association (EHRA), the Acute Cardiovascular Care Association (ACCA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), all of the ESC.

Professor Bulent Gorenek (Turkey), chairperson of the task force, said: "Sudden cardiac death is the leading cause of death in Europe, the US and other developed countries. These deaths are mainly due to cardiac arrhythmias. This is the first document to provide clear recommendations on how to manage patients with ACS who develop arrhythmias. This topic has received limited coverage in guidelines and at congresses, and clinicians have many unanswered questions."

He added: "During the last decade the clinical approach to arrhythmia management in ACS has changed. Previously, antiarrhythmic drugs were the mainstay of treatment but today interventions in the cardiac catheterisation lab are preferred. This shift has been so substantial that EHRA, ACCA and the EAPCI established a task force to define the current position."

The position paper provides recommendations on how to identify ACS patients at risk for arrhythmias and how to manage tachy- and bradyarrhythmias using drugs, devices and catheter-based approaches.

Clear guidance is provided on the use of antiarrhythmic drugs in patients with ACS and ventricular arrhythmias. Amiodarone is recommended as the first line antiarrhythmic drug, with lidocaine added as second line if necessary. In patients with ACS without ventricular arrhythmias, the paper says that prophylactic antiarrhythmic drug treatment should not be administered.

Professor Gorenek said: "The use of antiarrhythmic drugs for the treatment of sustained ventricular arrhythmias in ACS has been the subject of strong debate. No big randomised trials have been conducted on this topic. Our recommendations will help clinicians prescribe the most appropriate antiarrhythmic drug for the situation."

Another controversial area was the use of triple therapy (dual antiplatelet therapy and oral anticoagulation) in patients with ACS who develop atrial fibrillation. Professor Gorenek said: "Triple therapy is underused by clinicians which goes against current guidelines. We clarify when triple therapy should be used and for how long, and provide clear messages on the use of the non-vitamin K antagonist oral anticoagulants (NOACs)."

Novel detailed recommendations are given on the use of antithrombotic therapy in patients with atrial fibrillation and ACS, catheter ablation in ACS patients with sustained ventricular arrhythmias, and management of patients with arrhythmias who are undergoing primary percutaneous coronary intervention (pPCI) for ST-elevation myocardial infarction (STEMI).

An entire chapter is devoted to the management of arrhythmias in patients with acute myocardial infarction and cardiogenic shock. The document says that "regardless of the type of arrhythmia, treatment of the underlying cardiogenic shock with prompt revascularisation should be done as the primary procedure and should not be delayed by arrhythmia treatment".

Professor Gorenek said: "The management of patients with ACS and cardiac arrhythmias requires a multidisciplinary approach involving specialists in acute cardiac care, interventional cardiology and electrophysiology. The recommendations in this document should help all clinicians who manage these patients to provide the best treatment available."
Notes to editor

Authors: ESC Press Office
Tel: +34 670 521 210 (ESC Spokesperson Coordinator - Tanya Kenny)

About the European Society of Cardiology

The European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.

About ESC Congress 2014

ESC Congress is currently the world's largest international congress in cardiovascular medicine. ESC Congress 2014 takes place 30 August to 3 September at the Fira Gran Via congress centre in Barcelona, Spain.

About the European Heart Rhythm Association

The European Heart Rhythm Association (EHRA) is a registered branch of the ESC. Its aim is to improve the quality of life of the European population by reducing the impact of cardiac arrhythmias and reducing sudden cardiac death.

About the Acute Cardiovascular Care Association (ACCA)

The Acute Cardiovascular Care Association (ACCA) is a registered branch of the ESC. Its aim is to improve the quality of care and outcomes of patients with acute cardiovascular diseases.

About the European Association of Percutaneous Cardiovascular Interventions

The European Association of Percutaneous Cardiovascular Interventions (EAPCI) is a registered branch of the ESC. Its aim is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.

More information available on ESC Congress 365 after the scientific session: slides and webcast when available (

European Society of Cardiology

Related Atrial Fibrillation Articles from Brightsurf:

Atrial fibrillation less deadly than it used to be, but still cause for concern: BU study
A first-of-its-kind study by researchers from the Boston University School of Public Health (BUSPH) shows a decline in deaths related to atrial fibrillation (irregular heartbeat) over the last 45 years.

Postoperative atrial fibrillation does not impact on overall survival after esophagectomy
Volume 11, Issue 25 of Oncotarget reported that Administration of landiolol hydrochloride was found to be associated with reduced incidence of atrial fibrillation after esophagectomy for esophageal cancer in our previous randomized controlled trial.

People with atrial fibrillation live longer with exercise
More than 100,000 Norwegians have atrial fibrillation. They should be actively exercising for their health.

Atrial fibrillation among overweight people is not due to fat
In a recently published study, researchers from Aarhus University document that the risk of atrial fibrillation is not linked to the amount of body fat, but instead to large muscle mass, or more precisely, a high fat-free weight

Eating more protein could help ward off atrial fibrillation in women
Women who ate slightly more than the recommended daily amount of protein were significantly less likely to develop atrial fibrillation (AFib), a dangerous heart rhythm disorder that can lead to stroke and heart failure, when compared with those who consumed less protein, according to research being presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Zebrafish teach researchers more about atrial fibrillation
Genetic research in zebrafish at the University of Copenhagen has surprised the researchers behind the study.

Personalized medicine for atrial fibrillation
The study, published in Europace, uses signals from implantable devices -- pacemakers and defibrillators -- to analyze electrical signals in the heart during episodes of atrial fibrillation.

Prescribing anticoagulants in the ED for atrial fibrillation increases long-term use by 30%
Patients prescribed anticoagulants after a diagnosis of atrial fibrillation in the emergency department are more likely to continue long-term use of medications to treat the condition, according to research published in CMAJ (Canadian Medical Association Journal).

Anticoagulant benefits for atrial fibrillation decrease with age
The net clinical benefit of anticoagulants for atrial fibrillation (AF) -- one of the most important causes of irregular heartbeats and a leading cause of stroke -- decreases with age, as the risk of death from other factors diminishes their benefit in older patients, according to a study led by researchers at UC San Francisco.

Research improves understanding of mechanism of atrial fibrillation
Mouse model studies show that noncoding DNA regions linked to atrial fibrillation risk can display long-range regulatory functions directed at Pitx2 gene and in this way predispose to the condition.

Read More: Atrial Fibrillation News and Atrial Fibrillation Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to